Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our ...

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other best ...

Vertex’s effort to provide fertility support services to those on government insurance programs who want to take the ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

The Department of Health - Abu Dhabi (DoH), the regulator of the healthcare sector in the emirate, has announced the ...

Vertex Pharmaceuticals is a global biotechnology ... a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting ...

sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of ...

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated ... and is also developing therapies for sickle cell disease, type 1 diabetes, and other conditions.

Zimislecel, Vertex’s investigational fully differentiated islet cell therapy with standard immunosuppression, is in the Phase 3 portion of the ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

Vertex Pharmaceuticals Incorporated (Nasdaq ... The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to ...